サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：膠原病の世界市場：予測（2022年～2028年）
市場調査レポート
商品コード
1123356

膠原病の世界市場：予測（2022年～2028年）

Global Collagen Vascular Diseases Market Research and Forecast, 2022-2028
出版日: | 発行: Orion Market Research | ページ情報: 英文 120 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.53円
膠原病の世界市場：予測（2022年～2028年）
出版日: 2022年08月05日
発行: Orion Market Research
ページ情報: 英文 120 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の膠原病の市場規模は、予測期間中に約7.5%のCAGRで拡大すると予測されています。同市場の成長の主な推進要因の1つは、膠原病の有病率が上昇していることです。さらに、これらの疾患の治療オプションに向けた政府および非政府組織の取り組み強化や、創薬における高い進歩も、同市場の成長を後押ししています。

当レポートでは、世界の膠原病市場について調査し、市場の概要とともに、疾患タイプ別、診断別、治療薬別、エンドユーザー別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 レポートの概要

第2章 市場概要と洞察

第3章 競合情勢

  • 主要な企業分析
    • 概要
    • 財務分析
    • SWOT分析
  • 主要戦略分析
  • COVID-19が主要参入企業に与える影響

第4章 市場決定要因

  • 促進要因
  • 抑制要因
  • 機会

第5章 市場セグメンテーション

  • 世界の膠原病市場、疾患タイプ別
    • 自己免疫性膠原病
    • 遺伝性膠原病
  • 世界の膠原病市場、診断別
    • 全血算
    • 赤血球沈降速度（ESR）
    • C反応性タンパク質
    • リウマチ因子
    • その他（抗核抗体、顕微鏡分析による尿検査、血清クレアチニン）
  • 世界の膠原病市場、治療薬別
    • コルチコステロイド
    • 免疫抑制剤
    • エンドセリン受容体拮抗薬
    • その他（カルシウムチャネルブロッカー、PDE-5阻害剤、キレート剤）
  • 世界の膠原病市場、エンドユーザー別
    • 病院、診療所
    • 診断センター
    • 研究機関

第6章 地域分析

  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第7章 企業プロファイル

  • AbbVie Inc.
  • Amgen Inc.
  • Bayer AG`
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb Co.
  • Cadila Pharmaceuticals Ltd
  • Corbus Pharmaceuticals Holdings, Inc.
  • Cytori Therapeutics Inc.
  • Danaher Corp.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • GenWay Biotech Inc.
  • ImmuPharma PLC
  • Pfizer Inc.
  • Sanofi SA
  • Siemens Healthcare AG
  • Thermo Fisher Scientific, Inc.
  • Svar Life Science AB
  • MorphoSys AG
  • Merck & Co., Inc.
図表

LIST OF TABLES

  • 1. GLOBAL COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2020-2027 ($ MILLION)
  • 2. GLOBAL AUTOIMMUNE COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2020-2027 ($ MILLION)
  • 3. GLOBAL LUPUS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 4. GLOBAL RHEUMATOID ARTHRITIS MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 5. GLOBAL SCLERODERMA MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 6. GLOBAL HEREDITARY COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 7. GLOBAL COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY DIAGNOSTICS, 2020-2027 ($ MILLION)
  • 8. GLOBAL COMPLETE BLOOD COUNT MARKET RESEARCH AND ANALYSIS BY REGION 2020-2027 ($ MILLION)
  • 9. GLOBAL ERYTHROCYTE SEDIMENTATION RATE (ESR) MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 10. GLOBAL C-REACTIVE PROTEIN MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 11. GLOBAL RHEUMATOID FACTOR MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 12. GLOBAL COLLAGEN VASCULAR DISEASES FOR OTHERS (URINALYSIS WITH MICROSCOPIC ANALYSIS & SERUM CREATININE) MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 13. GLOBAL COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY THERAPEUTICS, 2020-2027 ($ MILLION)
  • 14. GLOBAL CORTICOSTEROIDS MARKET RESEARCH AND ANALYSIS BY REGION 2020-2027 ($ MILLION)
  • 15. GLOBAL IMMUNOSUPPRESSIVE AGENTS MARKET RESEARCH AND ANALYSIS BY REGION 2020-2027 ($ MILLION)
  • 16. GLOBAL ENDOTHELIN RECEPTOR ANTAGONISTS MARKET RESEARCH AND ANALYSIS BY REGION 2020-2027 ($ MILLION)
  • 17. GLOBAL COLLAGEN VASCULAR DISEASES FOR OTHERS (CALCIUM CHANNEL BLOCKERS, PDE-5 INHIBITORS & CHELATING AGENTS) MARKET RESEARCH AND ANALYSIS BY REGION 2020-2027 ($ MILLION)
  • 18. GLOBAL COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY END-USERS, 2020-2027 ($ MILLION)
  • 19. GLOBAL COLLAGEN VASCULAR DISEASES FOR HOSPITAL & CLINICS MARKET RESEARCH AND ANALYSIS BY REGION 2020-2027 ($ MILLION)
  • 20. GLOBAL COLLAGEN VASCULAR DISEASES FOR DIAGNOSTIC CENTERS MARKET RESEARCH AND ANALYSIS BY REGION 2020-2027 ($ MILLION)
  • 21. GLOBAL COLLAGEN VASCULAR DISEASES FOR RESEARCH INSTITUTES MARKET RESEARCH AND ANALYSIS BY REGION 2020-2027 ($ MILLION)
  • 22. GLOBAL COLLAGEN VASCULAR DISEASESMARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2020-2027 ($ MILLION)
  • 23. NORTH AMERICAN COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 24. NORTH AMERICAN COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2020-2027 ($ MILLION)
  • 25. NORTH AMERICAN COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY DIAGNOSTICS, 2020-2027 ($ MILLION)
  • 26. NORTH AMERICAN COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY THERAPEUTICS, 2020-2027 ($ MILLION)
  • 27. NORTH AMERICAN COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY END-USERS, 2020-2027 ($ MILLION)
  • 28. EUROPEAN COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 29. EUROPEAN COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2020-2027 ($ MILLION)
  • 30. EUROPEAN COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY DIAGNOSTICS, 2020-2027 ($ MILLION)
  • 31. EUROPEAN COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY THERAPEUTICS, 2020-2027 ($ MILLION)
  • 32. EUROPEAN COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY END-USERS, 2020-2027 ($ MILLION)
  • 33. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 34. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2020-2027 ($ MILLION)
  • 35. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY DIAGNOSTICS, 2020-2027 ($ MILLION)
  • 36. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY THERAPEUTICS, 2020-2027 ($ MILLION)
  • 37. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY END-USERS, 2020-2027 ($ MILLION)
  • 38. REST OF THE WORLD COLLAGEN VASCULAR DISEASES MARKE TRESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 39. REST OF THE WORLD COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2020-2027 ($ MILLION)
  • 40. REST OF THE WORLD COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY DIAGNOSTICS, 2020-2027 ($ MILLION)
  • 41. REST OF THE WORLD COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY THERAPEUTICS, 2020-2027 ($ MILLION)
  • 42. REST OF THE WORLD COLLAGEN VASCULAR DISEASES MARKET RESEARCH AND ANALYSIS BY END-USERS, 2020-2027 ($ MILLION)

LIST OF FIGURES

1. IMPACT OF COVID-19 ON GLOBAL COLLAGEN VASCULAR DISEASESMARKET, 2020-2027 (% MILLION)

2. IMPACT OF COVID-19 ON GLOBAL COLLAGEN VASCULAR DISEASESMARKET BY SEGMENT, 2020-2027 (% MILLION)

  • 3. RECOVERY OF GLOBAL COLLAGEN VASCULAR DISEASESMARKET, 2020-2027 (%)
  • 4. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SHARE BY DISEASE TYPE, 2020 VS 2027 (%)
  • 5. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SHARE BY DIAGNOSTICS, 2020 VS 2027 (%)
  • 6. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SHARE BY THERAPEUTICS , 2020 VS 2027 (%)
  • 7. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SHARE BY END-USERS, 2020 VS 2027 (%)
  • 8. GLOBAL COLLAGEN VASCULAR DISEASES MARKETSHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 9. GLOBAL AUTOIMMUNE COLLAGEN VASCULAR DISEASES MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 10. GLOBAL LUPUS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 11. GLOBAL RHEUMATOID ARTHRITIS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 12. GLOBAL SCLERODERMA MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 13. GLOBAL HEREDITARY COLLAGEN VASCULAR DISEASES MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 14. GLOBAL COMPLETE BLOOD COUNT MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 15. GLOBAL ERYTHROCYTE SEDIMENTATION RATE (ESR) MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 16. GLOBAL C-REACTIVE PROTEIN MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 17. GLOBAL RHEUMATOID FACTOR MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 18. GLOBAL COLLAGEN VASCULAR DISEASES FOR OTHERS (URINALYSIS WITH MICROSCOPIC ANALYSIS & SERUM CREATININE) MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 19. GLOBAL CORTICOSTEROIDS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 20. GLOBAL IMMUNOSUPPRESSIVE AGENTS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 21. GLOBAL ENDOTHELIN RECEPTOR ANTAGONISTS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 22. GLOBAL COLLAGEN VASCULAR DISEASES FOR OTHERS (CALCIUM CHANNEL BLOCKERS, PDE-5 INHIBITORS & CHELATING AGENTS) MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 23. GLOBAL HOSPITAL & CLINICS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 24. GLOBAL DIAGNOSTIC CENTERS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 25. GLOBAL RESEARCH INSTITUTES MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 26. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 27. US COLLAGEN VASCULAR DISEASES MARKET SIZE, 2020-2027($ MILLION)
  • 28. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, 2020-2027($ MILLION)
  • 29. UK COLLAGEN VASCULAR DISEASES MARKET SIZE, 2020-2027($ MILLION)
  • 30. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, 2020-2027($ MILLION)
  • 31. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, 2020-2027($ MILLION)
  • 32. ITALY COLLAGEN VASCULAR DISEASES MARKETSIZE, 2020-2027($ MILLION)
  • 33. SPAIN COLLAGEN VASCULAR DISEASES MARKETSIZE, 2020-2027($ MILLION)
  • 34. REST OF EUROPE COLLAGEN VASCULAR DISEASES MARKETSIZE, 2020-2027($ MILLION)
  • 35. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, 2020-2027($ MILLION)
  • 36. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, 2020-2027($ MILLION)
  • 37. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, 2020-2027($ MILLION)
  • 38. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, 2020-2027($ MILLION)
  • 39. REST OF ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, 2020-2027($ MILLION)
  • 40. REST OF THE WORLD COLLAGEN VASCULAR DISEASES MARKET SIZE, 2020-2027($ MILLION)
目次
Product Code: OMR2019516

Global Collagen Vascular Diseases Market Size, Share & Trends Analysis Report by Disease Type (Autoimmune Collagen Vascular Diseases and Hereditary Collagen Vascular Diseases), By Diagnostics (Complete Blood Count, Erythrocyte Sedimentation Rate (ESR), C-Reactive Protein, Rheumatoid Factor, and Others (Urinalysis with Microscopic Analysis & Serum Creatinine)), By Therapeutics (Corticosteroids, Immunosuppressive Agents, Endothelin Receptor Antagonists, and Others (Calcium Channel Blockers, PDE-5 Inhibitors & Chelating Agents)), and By End-Users (Hospital & Clinics, Diagnostic Centers, Research Institutes) Forecast, 2021-2027

The global market for collagen vascular diseases is projected to have a considerable CAGR of around 7.5% during the forecast period. Collagen vascular diseases are autoimmune diseases that happen when the immune system of the human body attacks its skin, organ, and tissues. It is a heritable disease that affects the joints, skin, blood vessels, or other vital organs of the body. One of the major driving factors for the growth of the market is the increasing prevalence of collagen vascular diseases. Moreover, increasing government and non-government organizational initiatives towards the treatment options for these diseases and high advancements in drug discovery are also fueling the growth of the Collagen Vascular Diseases market. On the contrary, the lack of reimbursement policies in various countries, such as Europe, and the high cost for the treatment of collagen vascular diseases will be restraining the growth of the market. However, a strong pipeline of the drug for diseases such as rheumatoid arthritis is creating a significant opportunity for future market growth.

Impact of COVID-19

Since the lockdown was imposed due to the COVID-19 pandemic, the number of patient visits to the hospitals has significantly reduced and only emergency and OPD services are available. Surgeons conduct various series of clinical tests before commencing any interventional process to determine the best suitable treatment option for the patient. As the patient's visit to the hospital has been reduced therefore it reduced the diagnostic tests and decrease the sales of therapeutics for collagen vascular diseases.

Segmental Outlook

The global collagen vascular diseases market is segmented based on disease type, diagnostics, therapeutics, and end-users. Based on the disease type, the market is classified into autoimmune collagen vascular diseases and hereditary collagen vascular diseases. Further based on diagnostics, the market is segregated into complete blood count, erythrocyte sedimentation rate (ESR), C-Reactive protein, rheumatoid factor, and others (Urinalysis with Microscopic Analysis & Serum Creatinine), based on therapeutics, the market is classified into corticosteroids, immunosuppressive agents, endothelin receptor antagonists and others (Calcium Channel Blockers, PDE-5 Inhibitors & Chelating Agents). Furthermore, based on end-user, the market is segmented into hospitals & clinics, diagnostic centers, research institutes.

Global Collagen Vascular Diseases Market Share by autoimmune collagen vascular diseases type, 2020(%)

Global Collagen Vascular Diseases Market Share

Rheumatoid Arthritis is estimated to have a significant share in the Global Collagen Vascular Diseases market

Among diseases type, rheumatoid Arthritis is projected to have a significant share during the forecast period. Rheumatoid arthritis is a chronic autoimmune, systemic inflammatory disease that causes joint swelling, stiffness, pain, joint destruction, and disability. The major factors that cause rheumatoid arthritis includes are increasing adoption of a sedentary lifestyle among people including smoking, physical inactivity resulting in obesity. The fast-moving lifestyle and urbanization have increased the sedentary lifestyle in developed and emerging countries. As a result, rheumatoid arthritis is expected to increase with the rise in sedentary lifestyles across the globe. Moreover, the rising prevalence of diabetes also cumulating the growth of rheumatoid arthritis, for instance, according to the Arthritis Foundation, approximately half of all adults with diabetes also have rheumatoid arthritis. Therefore, rheumatoid arthritis is one of the most prevailing diseases among the disease's type and further contribute to the growth of the market.

Regional Outlook

Geographically, the global Collagen Vascular Diseases market is classified into four major regions including North America (the US and Canada), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia-Pacific (India, China, Japan, and Rest of Asia-Pacific), and Rest of the World (Latin America and the Middle East and Africa (MEA)). North America is projected to have a significant share in the collagen vascular diseases market due to factors including raising awareness among the population about collagen vascular diseases, increased healthcare spending. According to HealthAffairs, in 2019, US healthcare spending increased by 4.6% to $3.8 trillion. Moreover, advanced drug discoveries for the treatment of these diseases also contributing to the growth of the collagen vascular diseases market in the region.

Global Collagen Vascular Diseases Market Growth, by Region 2020-2027

Global Collagen Vascular Diseases Market region

Asia-Pacific to have a considerable CAGR in the global Collagen Vascular Diseases market

Asia-Pacific is estimated to have significant growth in the global collagen vascular diseases market. The growth is attributed to factors that include the rapid development of medical infrastructure facilities in the region, and increasing healthcare spending in the countries such as China and India. Moreover, the growing adoption of urban lifestyle among the population is expanding base for patients along with favorable regulatory policies for biosimilars will boost the growth of therapeutics for the collagen vascular diseases in the Asia Pacific region.

Market Players Outlook

The key players in the collagen vascular diseases market contributing significantly by providing different types of products and increasing their geographical presence across the globe. The key players of the market include AbbVie Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, Inc., Pfizer Inc, Beckman Coulter, Inc., and Bayer AG, among others. These market players adopt various strategies such as product launches, partnerships, collaborations, mergers, and acquisitions to sustain a strong position in the market. In June 2019, F. Hoffmann-La Roche Ltd announced the positive results for NOBILITY, phase II clinical trials by investigating the safety and efficacy of Gazyva for people with proliferative lupus nephritis. The clinical study met its primary and secondary endpoints by showing improved overall renal responses. With the approval of this product, the company will be one of the first companies offering antibody treatment for the life-threatening conditions under lupus nephritis as there are no FDA -approved treatments for the following disease till now.

The Report Covers

Market value data analysis of 2020 and forecast to 2027.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global Collagen Vascular Diseases market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on the Global Collagen Vascular Diseases Industry
  • Recovery Scenario of Global Collagen Vascular Diseases Industry
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Regulations

3. Competitive Landscape

  • 3.1. key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
  • 3.2. Key strategy analysis
  • 3.3. Impact of Covid on key players

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Collagen Vascular Diseases Market by Disease Type
    • 5.1.1. Autoimmune Collagen Vascular Diseases
      • 5.1.1.1. Lupus
      • 5.1.1.2. Rheumatoid Arthritis
      • 5.1.1.3. Scleroderma
    • 5.1.2. Hereditary Collagen Vascular Diseases
  • 5.2. Global Collagen Vascular Diseases Market by Diagnostics
    • 5.2.1. Complete Blood Count
    • 5.2.2. Erythrocyte Sedimentation Rate (ESR)
    • 5.2.3. C-Reactive Protein
    • 5.2.4. Rheumatoid Factor
    • 5.2.5. Others (Antinuclear Antibodies, Urinalysis with Microscopic Analysis & Serum Creatinine)
  • 5.3. Global Collagen Vascular Diseases Market by Therapeutics
    • 5.3.1. Corticosteroids
    • 5.3.2. Immunosuppressive Agents
    • 5.3.3. Endothelin Receptor Antagonists
    • 5.3.4. Others (Calcium Channel Blockers, PDE-5 Inhibitors & Chelating Agents)
  • 5.4. Global Collagen Vascular Diseases Market by End-Users
    • 5.4.1. Hospital & Clinics
    • 5.4.2. Diagnostic Centers
    • 5.4.3. Research Institutes

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. South Korea
    • 6.3.5. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. AbbVie Inc.
  • 7.2. Amgen Inc.
  • 7.3. Bayer AG`
  • 7.4. Bio-Rad Laboratories, Inc.
  • 7.5. Bristol-Myers Squibb Co.
  • 7.6. Cadila Pharmaceuticals Ltd
  • 7.7. Corbus Pharmaceuticals Holdings, Inc.
  • 7.8. Cytori Therapeutics Inc.
  • 7.9. Danaher Corp.
  • 7.10. Eli Lilly and Co.
  • 7.11. F. Hoffmann-La Roche Ltd.
  • 7.12. GenWay Biotech Inc.
  • 7.13. ImmuPharma PLC
  • 7.14. Pfizer Inc.
  • 7.15. Sanofi SA
  • 7.16. Siemens Healthcare AG
  • 7.17. Thermo Fisher Scientific, Inc.
  • 7.18. Svar Life Science AB
  • 7.19. MorphoSys AG
  • 7.20. Merck & Co., Inc.